W. Pao

W. Pao, F. Michor, J. Chmielecki, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

J. Berlin, W. Pao, J. Sosman, 2014, The oncologist.

Constitutive activation of Raf-1 induces glioma formation in mice.

W. Pao, E. Holland, H. Momota, 2008, Neoplasia.

Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

William Pao, Marc Ladanyi, Geoffrey R. Oxnard, 2010, Clinical Cancer Research.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma.

M. Ladanyi, C. Sima, M. Kris, 2010 .

Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer

W. Pao, Helena A. Yu, H. Yu, 2013, Nature Reviews Clinical Oncology.

Tumorigenesis and Neoplastic Progression Tumor Progression Stage and Anatomical Site Regulate Tumor-Associated Macrophage and Bone Marrow-Derived Monocyte Polarization

W. Pao, L. Dwyer-Nield, A. Malkinson, 2010 .

BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models

W. Pao, A. Malkinson, D. Christiani, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integration of Molecular Profiling into the Lung Cancer Clinic

M. Ladanyi, A. Iafrate, M. Kris, 2009, Clinical Cancer Research.

EGFR Mutations in Lung Adenocarcinomas

M. Ladanyi, M. Kris, W. Pao, 2010 .

EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial.

M. Ladanyi, M. Kris, W. Pao, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, M. Ladanyi, A. Iafrate, 2013 .

Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

W. Pao, X. Shu, W. Zheng, 2015, JAMA oncology.

Erratum: BAC Consensus Conference, November 4-6, 2004: Epidemiology, pathogenesis, and preclinical models (Journal of Thoracic Oncology (2006) 1, (S2-S7))

W. Pao, A. Malkinson, Kwok-Kin Wong, 2007 .

A phase II trial of salirasib in patients with stage IIIB/IV lung adenocarcinoma enriched for KRAS mutations.

M. Kris, W. Pao, Gregory Riely, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

W. Gerald, W. Travis, W. Pao, 2007, The Journal of clinical investigation.

Serum levels of surfactant protein D are increased in mice with lung tumors.

W. Pao, L. Dwyer-Nield, A. Malkinson, 2003, Chest.

Serum levels of surfactant protein D are increased in mice with lung tumors.

L. D. Nielsen, W. Pao, L. Dwyer-Nield, 2003, Cancer research.

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

P. Stephens, W. Pao, J. Sosman, 2013, Clinical Cancer Research.

Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers

W. Pao, H. Ji, Rong Fang, 2010, Acta Pharmacologica Sinica.

DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment-A catalogue of clinically relevant somatic mutations in lung cancer.

W. Pao, M. Levy, J. Andrews, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated genomic analysis of lung adenocarcinomas identifies loss of the MAPK phosphatase gene DUSP4 in most EGFR mutant tumors

W. Gerald, C. Brennan, M. Ladanyi, 2007 .

EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.

W. Pao, K. Offit, Gregory Riely, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Disruption ofepithelial y6T cellrepertoires bymutation ofthe Syktyrosine kinase (antigen receptor generearrangement/lymphocyte development/tissue compartmentalization/Rag2Syk chimeras)

W. Pao, 1996 .

ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS

W. Pao, E. Smit, S. Gettinger, 2012 .

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.

M. Ladanyi, M. Kris, V. Rusch, 2010, AJR. American journal of roentgenology.

Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers

N. Girard, M. Ladanyi, C. Begg, 2009, Clinical Cancer Research.

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors

Chris Sander, William Pao, Stephen Broderick, 2009, Oncogene.

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

V. Seshan, M. Ladanyi, M. Kris, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.

N. Girard, M. Ladanyi, V. Rusch, 2010, Chest.

Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

William Pao, Marc Ladanyi, Gregory J Riely, 2006, Clinical Cancer Research.

The Epidermal Growth Factor Receptor D761Y Mutation and Effect of Tyrosine Kinase Inhibitor

W. Pao, Y. Gong, M. Balak, 2007 .

Response to CCR-07-0070

W. Pao, Y. Gong, M. Balak, 2007, Clinical Cancer Research.

Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.

M. Ladanyi, M. Kris, V. Rusch, 2009, Archives of pathology & laboratory medicine.

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.

William Pao, Marc Ladanyi, Vincent A. Miller, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective trial with preoperative gefitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy.

M. Ladanyi, M. Kris, V. Rusch, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance

H. Varmus, W. Pao, D. Klimstra, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib

M. Kris, W. Pao, C. Cordon-Cardo, 2004 .

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

William Pao, Marc Ladanyi, M. Ladanyi, 2008, Modern Pathology.

D2-01: Prospective trial of preoperative gefitinib to correlate response with EGFR exon 19 and 21 mutations and to select patients for adjuvant gefitinib

M. Ladanyi, Binsheng Zhao, M. Kris, 2007 .

Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.

R. Wilson, M. Ladanyi, M. Kris, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

M. Ladanyi, M. Kris, W. Pao, 2008, Clinical Cancer Research.

Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4

R. Wilson, L. Fulton, E. Mardis, 2007, PloS one.

Rapamycin prevents the development and progression of mutant EGFR lung tumors with the acquired resistance mutation T790M

P. Jänne, W. Pao, P. Dennis, 2014 .

Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases

M. Kris, W. Pao, Gregory Riely, 2018, Cancer.

Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications

William Pao, Erika Avila-Tang, J. Herman, 2009, Clinical Cancer Research.

γδ T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells

W. Pao, L. Wen, A. Hayday, 1996, Current Biology.

and Illustrate the Association of CD4 with Th2 Cells Phenotypically and Functionally as Th1/Th2 Cell Clones Can Be Defined δ γ Primary

D. F. Barber, W. Pao, L. Wen, 2017 .

Germinal center formation, immunoglobulin class switching, and autoantibody production driven by "non alpha/beta" T cells

W. Pao, L. Wen, F. Wong, 1996, The Journal of experimental medicine.

Postoperative radiotherapy in the treatment of extremity soft tissue sarcomas.

W. Pao, M. Pilepich, 1990, International journal of radiation oncology, biology, physics.

Germinal center formation in mice lacking αβ T cells

W. Pao, A. Hayday, I. Maclennan, 1996 .

Erlotinib in lung cancer.

M. Ladanyi, W. Pao, V. Miller, 2005, The New England journal of medicine.

T Cell Receptor, γδ

W. Pao, A. Hayday, 1998 .

Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling.

W. Pao, C. Meador, 2015, Cancer discovery.

Primary gamma delta cell clones can be defined phenotypically and functionally as Th1/Th2 cells and illustrate the association of CD4 with Th2 differentiation.

W. Pao, L. Wen, F. Wong, 1998, Journal of immunology.

Intrathymic delta selection events in gammadelta cell development.

W. Pao, A. Hayday, M. Owen, 1997, Immunity.

Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.

H. Ji, W. Pao, Rong Fang, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.

W. Pao, H. Wakelee, C. Liang, 2014 .

Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase.

T. Pawson, W. Pao, A. Hayday, 1996, Proceedings of the National Academy of Sciences of the United States of America.

A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers.

C. Sima, C. Rudin, M. Kris, 2015 .

Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.

P. Stephens, R. Yelensky, W. Pao, 2014, Cancer discovery.

Wilms' tumor: reduced-dose radiotherapy in advanced-stage Wilms' tumor with favorable histology.

W. Pao, D. Fairclough, E. Douglass, 1990, International journal of radiation oncology, biology, physics.

Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib.

M. Ladanyi, W. Pao, Gregory Riely, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns and processes of somatic mutations in nine major cancers

Zhongming Zhao, P. Jia, W. Pao, 2014, BMC Medical Genomics.

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer

William Pao, Zhongming Zhao, Ronglai Shen, 2014, Nature Medicine.

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

William Pao, Michael Hölzel, Martin Peifer, 2011, Clinical Cancer Research.

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

William Pao, Juliann Chmielecki, W. Pao, 2010, Nature Reviews Cancer.

Local-regional non-rhabdomyosarcomatous soft tissue sarcomas of the head and neck.

W. Pao, I. Fleming, C. Pratt, 1990, International journal of radiation oncology, biology, physics.

Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer.

Junfeng Xia, Peilin Jia, William Pao, 2015, Methods.

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

William Pao, Gregory J Riely, D Ross Camidge, 2014, Cancer discovery.

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

Amanda R. Kulick, M. Ladanyi, W. Pao, 2017, Cancer research.

Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis

W. Pao, Haiquan Chen, Yuan Li, 2012, Clinical Cancer Research.

Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013, Clinical Cancer Research.

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

H. Ji, W. Pao, Haiquan Chen, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01

Susan M. Chang, R. Wilson, M. Prados, 2005, Clinical Cancer Research.

Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors : Tissue Analysis fromNorth

Susan M. Chang, R. Wilson, M. Prados, 2005 .

The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers

Chris Sander, Fang Fang, William Pao, 2009, Proceedings of the National Academy of Sciences.

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.

William Pao, Marc Ladanyi, Valerie Rusch, 2008, The Journal of molecular diagnostics : JMD.

Oncogenes come of age.

H. Varmus, W. Pao, K. Politi, 2005, Cold Spring Harbor symposia on quantitative biology.

Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling

W. Pao, M. Levy, M. Sanders, 2014, Breast Cancer Research and Treatment.

Maximizing the benefits of off-target kinase inhibitor activity.

W. Pao, M. Red Brewer, 2013, Cancer Discovery.

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Roman K. Thomas, W. Pao, C. Liang, 2011, Cancer research.

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

Li Ding, William Pao, Elaine R Mardis, 2008, Cancer research.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

William Pao, Peter Ballard, Hailing Jin, 2014, Cancer discovery.

AACR Cancer Progress Report 2016

William Pao, Thomas J. Smith, Thomas J Smith, 2016, Clinical Cancer Research.

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies

W. Pao, D. Fabrizio, J. Chmielecki, 2017, Genome Medicine.

Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.

W. Pao, B. Kuhn, A. Kuglstatter, 2022, Journal of medicinal chemistry.

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

M. Kris, P. Jänne, W. Pao, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

M. Ladanyi, M. Kris, W. Pao, 2012, Cancer discovery.

Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance

Junfeng Xia, Peilin Jia, William Pao, 2013, Genome research.

resistance lines identifies spectrum of DNA changes associated with drug inhibitor-sensitive and-resistant EGFR mutant lung cancer cell Next-generation sequencing of paired tyrosine kinase Material Supplemental

Zhongming Zhao, P. Jia, W. Pao, 2013 .

Intrathymic δ Selection Events in γδ Cell Development

W. Pao, A. Hayday, M. Owen, 1997 .

Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies

C. Sander, B. Taylor, N. Schultz, 2010, Nature Genetics.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

William Pao, Hongbin Ji, Nicolas Girard, 2011, European Respiratory Journal.

Clinical Applications of Kinase Inhibitors in Solid Tumors

N. Girard, W. Pao, 2010 .

Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer

W. Pao, Gregory Riely, V. Miller, 2006, Clinical Cancer Research.

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

M. Ladanyi, W. Pao, Gregory Riely, 2008, Clinical Cancer Research.

MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis

Zhongming Zhao, P. Jia, W. Pao, 2014, Genome Biology.

Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204‐PDGFRB fusion in a patient with recurrent T‐ALL and an associated myeloproliferative neoplasm

Annette S. Kim, N. Socci, A. Viale, 2012, Genes, chromosomes & cancer.

Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives

Qingguo Wang, Junfeng Xia, Peilin Jia, 2013, Briefings Bioinform..

51 – Biology of Lung Cancer

W. Pao, P. Massion, L. Sequist, 2016 .

Therapeutics , Targets , and Chemical Biology Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

E. Stanchina, Roman K. Thomas, W. Pao, 2011 .

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

W. Pao, L. Horn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

William Pao, Harold Varmus, Daniel K Treiber, 2005, Proceedings of the National Academy of Sciences of the United States of America.

MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

Zhongming Zhao, A. Iafrate, P. Jia, 2016, The oncologist.

Genetic predictors of MEK dependence in non-small cell lung cancer.

William Pao, Barry S Taylor, Neal Rosen, 2008, Cancer research.

Cancer Biology and Signal Transduction a Meta-analysis of Somatic Mutations from next Generation Sequencing of 241 Melanomas: a Road Map for the Study of Genes with Potential Clinical Relevance

Junfeng Xia, Peilin Jia, William Pao, 2022 .

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Zhongming Zhao, N. Socci, A. Viale, 2010, Nucleic acids research.

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Junfeng Xia, Peilin Jia, William Pao, 2012, Cancer discovery.

Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning.

N. Rothman, R. Vermeulen, W. Pao, 2013, Respiratory medicine.

Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers

Peilin Jia, William Pao, Zhongming Zhao, 2013, Genome Medicine.

A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development

William Pao, Lawrence H. Schwartz, Binsheng Zhao, 2010, Clinical Cancer Research.

ponse Evaluation to Aid Biomarker Development

M. Ladanyi, L. Schwartz, M. Kris, 2010 .

Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women.

Hongbing Shen, Chien-Jen Chen, N. Rothman, 2016, Human molecular genetics.

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types.

Jian Su, Wen Tan, Paolo Vineis, 2015, Journal of the National Cancer Institute.

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types

Alison P. Klein, William Wheeler, Li Jin, 2015 .

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

William Pao, John D. Minna, Yu Shyr, 2014, JAMA.

Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas

N. Girard, A. Lash, A. Viale, 2009, Clinical Cancer Research.

Phase II study of gefitinib treatment in advanced thymic malignancies

W. Pao, P. Loehrer, M. Burns, 2005 .

Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors

W. Pao, H. Moses, P. Clark, 2017, Molecular oncology.

Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report

N. Girard, A. Viale, M. Ladanyi, 2010, Clinical Cancer Research.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Juswinder Singh, W. Pao, T. van Dyke, 2013, Cancer discovery.

Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome.

H. Ji, W. Pao, Rong Fang, 2014, Cancer letters.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2013, Cancer.

Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

M. Ladanyi, C. Azzoli, W. Pao, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive Biomarkers and Personalized Medicine Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer : Distinct Natural History of Patients with Tumors Harboring the T 790 M Mutation

M. Ladanyi, C. Sima, M. Kris, 2011 .

Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors

W. Pao, N. Rosen, D. Solit, 2007, PloS one.

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

N. Socci, A. Viale, M. Ladanyi, 2011, Science Translational Medicine.

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

M. Ladanyi, M. Kris, W. Pao, 2011, Clinical Cancer Research.

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations

M. Ladanyi, M. Kris, C. Azzoli, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired resistance to TKIs in solid tumours: learning from lung cancer

W. Pao, L. Sequist, D. Camidge, 2014, Nature Reviews Clinical Oncology.

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

W. Pao, M. Eck, M. Lemmon, 2013, Proceedings of the National Academy of Sciences.

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Roman K. Thomas, W. Pao, R. Küppers, 2012, Clinical Cancer Research.

EGFR mutant lung cancer.

W. Pao, Y. Gong, 2012, Current topics in microbiology and immunology.

Cancer Therapy : Preclinical See commentary by Crystal and Shaw , p . 4479 Differential Protein Stability and ALK Inhibitor Sensitivity of EML 4-ALK Fusion Variants

Roman K. Thomas, W. Pao, M. Peifer, 2012 .

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

William Pao, Andrei I Holodny, Geoffrey R Oxnard, 2011, Neuro-oncology.

Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations

M. Kris, D. Tenen, W. Pao, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

W. Pao, V. Miller, A. Lassman, 2010, Journal of Neuro-Oncology.

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

William Pao, Thomas Zander, Martin Peifer, 2009, Proceedings of the National Academy of Sciences.

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

P. Jänne, D. Tenen, W. Pao, 2008, Clinical Cancer Research.

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.

H. Varmus, W. Pao, K. Politi, 2006, Genes & development.

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, A. Iafrate, C. Rudin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract B10: Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.

X. Chen, M. Ladanyi, E. Stanchina, 2014 .

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

William Pao, Yumei Pan, Lu Wang, 2012, Proceedings of the National Academy of Sciences.

Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib

M. Ladanyi, C. Sima, M. Kris, 2011, Clinical Cancer Research.

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

M. Ladanyi, W. Pao, M. Arcila, 2011, Clinical Cancer Research.

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, A. Iafrate, C. Rudin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

William Pao, Jason A Koutcher, Ronglai Shen, 2009, The Journal of clinical investigation.

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

M. Meyerson, C. Mermel, B. Weir, 2009, Cancer research.

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

W. Pao, K. Politi, R. Somwar, 2007, PLoS medicine.

How genetically engineered mouse tumor models provide insights into human cancers.

W. Pao, K. Politi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas

H. Ji, W. Pao, Rong Fang, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genetically informed lung cancer medicine

A. Iafrate, W. Pao, Zengliu Su, 2011, The Journal of pathology.

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

William Pao, Maria E Arcila, Gregory J Riely, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).

M. Kris, W. Pao, V. Miller, 2004, Seminars in cancer biology.

From academia to industry: a road more travelled.

W. Pao, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment

William Pao, Jeremy L. Warner, Ravi V. Atreya, 2016, J. Am. Medical Informatics Assoc..

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Peilin Jia, William Pao, Zhongming Zhao, 2014, Cell reports.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

William Pao, Vandana G Abramson, Jill Gilbert, 2014, The oncologist.

New approaches to targeted therapy in lung cancer.

W. Pao, 2012, Proceedings of the American Thoracic Society.

Comprehensivegenomiccharacterization of squamous cell lung cancers

Joshua M. Stuart, Derek Y. Chiang, A. Sivachenko, 2012 .

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells

William Pao, Franziska Michor, Kevin Leder, 2015, Cancer informatics.

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

W. Pao, N. Gray, D. Colvin, 2016, Cancer research.

EPHA2BlockadeOvercomesAcquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

W. Pao, N. Gray, D. Colvin, 2016 .

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

P. Febbo, K. Aldape, M. Ladanyi, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

William Pao, Valerie Rusch, Christopher Azzoli, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib

X. Chen, A. Viale, M. Kris, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Juliann Chmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR-Mutant Non

N. Socci, A. Viale, M. Ladanyi, 2011 .

Predictive Biomarkers and Personalized Medicine Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T 790 M Mutation Using a Locked Nucleic Acid-Based Assay

M. Ladanyi, M. Kris, W. Pao, 2011 .

Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.

M. Ladanyi, W. Pao, Q. Pan, 2005, The Journal of molecular diagnostics : JMD.

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.

W. Pao, J. Shih, Yeun-Chung Chang, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

William Pao, Yang Zhang, Hongbin Ji, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers

A. Iafrate, H. Ji, W. Pao, 2011, PloS one.

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

E. Giovannetti, G. Peters, R. Bernards, 2015, Oncotarget.

High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507)

William Pao, Martin Peifer, Ronglai Shen, 2009, PloS one.

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.

C. Sima, C. Rudin, M. Kris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Robert M. Vogel, M. Ladanyi, W. Pao, 2016, Science Signaling.

Objective Radiographic Response to MEK Inhibitor Therapy in a Patient with a Metastatic Melanoma with a BRAF

Zhongming Zhao, J. Netterville, P. Jia, 2012 .

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

H. Ji, Roman K. Thomas, W. Pao, 2016, Clinical Cancer Research.

Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients

Fei Li, William Pao, Franziska Michor, 2015, PloS one.

Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer

W. Pao, J. Chmielecki, 2010, Clinical Cancer Research.

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.

W. Pao, P. Fisher, J. Dry, 2015, Cancer research.

Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

W. Pao, F. Michor, P. Mallick, 2011, Molecular pharmaceutics.

Further advances in genetically informed lung cancer medicine.

W. Pao, C. Nebhan, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

NovelD761YandCommonSecondary T790MMutationsinEpidermal Growth Factor Receptor^Mutant LungAdenocarcinomaswith AcquiredResistance toKinase Inhibitors

M. Ladanyi, M. Kris, W. Pao, 2006 .

JAK 2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors

Robert M. Vogel, M. Ladanyi, E. Stanchina, 2016 .

Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

F. Hyder, W. Pao, K. Politi, 2015, Clinical Cancer Research.

HER2 Amplifi cation: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR

M. Ladanyi, M. Kris, E. Stanchina, 2012 .

HER 2 Amplifi cation : A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFR T 790 M Mutation

M. Ladanyi, M. Kris, E. Stanchina, 2012 .

Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.

J. Jett, W. Pao, Y. Yatabe, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009 .

[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases

William Pao, Valerie Rusch, Charuhas Deshpande, 2009, The American journal of surgical pathology.

A prospective study to correlate EGFR mutations with gefitinib response

H. Varmus, M. Ladanyi, M. Kris, 2005 .

Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013 .

Translating genomic information into clinical medicine: Lung cancer as a paradigm

William Pao, Mia A Levy, W. Pao, 2012, Genome research.

Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise

M. Kris, C. Azzoli, W. Pao, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

M. Kris, C. Azzoli, W. Pao, 2011, Clinical Cancer Research.

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

H. Groen, W. Pao, E. Smit, 2017, Lung cancer.

Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

X. Chen, Zhongming Zhao, M. Ladanyi, 2014, Molecular Cancer Therapeutics.

Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never‐smoking women in Asia: a report from the female lung cancer consortium in Asia

B. Qian, Hongbing Shen, Chien-Jen Chen, 2015, International journal of cancer.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

M. Kris, C. Azzoli, W. Pao, 2007, Cancer.

Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas

William Pao, Lei Shen, Ting Ye, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Practical management of patients with non-small-cell lung cancer treated with gefitinib.

M. Kris, W. Pao, L. Ben-Porat, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer

W. Pao, J. Andrews, L. Horn, 2011, Cancer journal.

Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.

P. Jänne, W. Pao, Kwok-Kin Wong, 2014, Cell reports.

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

William Pao, Rebecca S. Cook, Carlos L. Arteaga, 2011, Proceedings of the National Academy of Sciences.

A protein knockdown strategy to study the function of β-catenin in tumorigenesis

H. Varmus, W. Pao, Jianxuan Zhang, 2003, BMC Molecular Biology.

A new target for therapy in squamous cell carcinoma of the lung.

W. Pao, K. Ohashi, 2011, Cancer discovery.

Estimation of the likelihood of epidermal growth factor receptor (EGFR) mutations based on cigarette smoking history in patients with adenocarcinoma of the lung

R. Wilson, M. Kris, V. Rusch, 2005 .

Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

William Pao, Mark C. Kelley, Ann Richmond, 2012, PloS one.

Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone

P. Jänne, A. Vortmeyer, W. Pao, 2015, OncoTarget.

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma

X. Chen, Zhongming Zhao, M. Berger, 2015, Oncotarget.

Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.

W. Pao, J. Sosman, E. Chan, 2013, AJR. American journal of roentgenology.

Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method

M. Ladanyi, W. Pao, 2007, Clinical Cancer Research.

Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

C. Sima, M. Kris, C. Azzoli, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer

Lei Wang, William Pao, Bin Li, 2014, Clinical Cancer Research.

Defining clinically relevant molecular subsets of lung cancer

W. Pao, 2006, Cancer Chemotherapy and Pharmacology.

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

H. Groen, W. Pao, E. Smit, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer

William Pao, M. Kris, C. Azzoli, 2006, Cancer.

Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.

W. Pao, John Calvin Reed, O. Spleiss, 2018, Cancer discovery.

Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients.

W. Pao, N. Beckford, E. Douglass, 1989, International journal of radiation oncology, biology, physics.

Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging

W. Pao, J. Jenkins, A. Green, 1991, Cancer.

The NIH-led research response to COVID-19

W. Pao, D. Lowy, J. Woodcock, 2023, Science.

Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

M. Kris, C. Azzoli, W. Pao, 2007 .

Monitoring EGFR-mutant lung cancers by means of the blood.

W. Pao, 2006, Journal of Thoracic Oncology.

Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507).

M. Ladanyi, W. Pao, J. Teruya-Feldstein, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

M. Kris, W. Pao, J. Warner, 2010 .

Characterizing Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in an EGFR Mutant Lung Adenocarcinoma Cell Line

W. Pao, K. Ohashi, Jing Sun, 2013 .

Mutational and Clinicopathologic Characteristics of AdSqLCs

W. Pao, Haiquan Chen, Yuan Li, 2022 .

Melanoma BRAF Fusions—Response

P. Stephens, W. Pao, J. Sosman, 2014, Clinical Cancer Research.

Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?

M. Kris, E. Venkatraman, W. Pao, 2004, Journal of the National Cancer Institute.

Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistancein vitro.

W. Pao, T. Mitsudomi, K. Ohashi, 2013 .

Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI).

M. Ladanyi, M. Kris, W. Pao, 2010 .

A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC).

W. Pao, D. Carbone, A. Hutchison, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer.

William Pao, Marc Ladanyi, Vincent A. Miller, 2006 .

Influence of site of expression on the fetal gamma delta T-cell receptor repertoire.

W. Pao, S. Kyes, A. Hayday, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

M. Kris, C. Azzoli, W. Pao, 2005 .

NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

P. Febbo, K. Aldape, M. Ladanyi, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular on/off switch.

M. Kris, W. Pao, Gregory Riely, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Somatic mutation spectrum of non-small cell lung cancers (NSCLCs) from African Americans (AAs).

W. Pao, D. Carbone, Y. Shyr, 2012 .

Hodgkin’s Disease in Children

W. Pao, Howard Je, S. JarpaYanez, 1989, Cancer Treatment and Research.

Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma.

W. Pao, S. Ashton, D. Cross, 2013 .

Germinal center formation in mice lacking alpha beta T cells.

W. Pao, A. Hayday, I. Maclennan, 1996, European Journal of Immunology.

9018 POSTER DISCUSSION Identification of Driver Mutations in Tumour Specimens From 1000 Patients With Lung Adenocarcinoma for the Lung Cancer Mutation Consortium (LCMC)

C. Rudin, M. Kris, J. Minna, 2011 .

Real-world utilization of EGFR TKI therapies and treatment outcomes in patients with advanced EGFR-sensitizing mutation-positive NSCLC.

W. Pao, Gregory Riely, R. Doebele, 2019, Journal of Clinical Oncology.

Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

W. Pao, I. Mellinghoff, K. Politi, 2009, The Journal of clinical investigation.

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comprehensive genomic characterization of squamous cell lung cancers

Joshua M. Stuart, Brian D. O’Connor, Charles J. Vaske, 2012, Nature.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

W. Pao, M. Ranson, Hailing Jin, 2014, Cancer discovery.

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

M. Ladanyi, C. Sima, M. Kris, 2013, Clinical Cancer Research.

Somatic mutations affect key pathways in lung adenocarcinoma

Brian H. Dunford-Shore, T. Fennell, K. Cibulskis, 2008, Nature.

Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.

W. Pao, Rong Fang, Haiquan Chen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

H. Groen, W. Pao, E. Smit, 2014, Cancer discovery.

Characterizing the cancer genome in lung adenocarcinoma

Derek Y. Chiang, S. Gabriel, E. Lander, 2007, Nature.

AACR Cancer Progress Report 2016

Thomas J. Smith, S. Armstrong, R. Deberardinis, 2016, Clinical Cancer Research.

Azd9291, an Irreversible Egfr Tki, Overcomes T790m-mediated Resistance to Egfr Inhibitors in Lung Cancer Oncology Innovative Medicines And

W. Pao, D. Cross, R. Rowlinson, 2022 .

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains

W. Pao, Yang Zhang, Rong Fang, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.

The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor. Authors' reply

S. Toyooka, W. Pao, K. Kiura, 2007 .

A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development

M. Ladanyi, L. Schwartz, Binsheng Zhao, 2010, Clinical Cancer Research.

Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.

J. Jett, W. Pao, Y. Yatabe, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

t(5;6)(q33-34;q23) CEP85L/PDGFRB

W. Pao, J. Chmielecki, 2013 .

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

M. Ladanyi, M. Kris, W. Pao, 2012, Cancer discovery.

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor

E. Giovannetti, G. Peters, R. Bernards, 2015, Oncotarget.

ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.

M. Ladanyi, A. Iafrate, C. Rudin, 2012 .

EGFR mutation, immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC

M. Ladanyi, M. Kris, W. Pao, 2005 .